STOCK TITAN
  1. Home
  2. News
  3. CLRB

Cellectar Biosciences Inc - CLRB STOCK NEWS

Welcome to our dedicated news page for Cellectar Biosciences (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cellectar Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cellectar Biosciences's position in the market.

News
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Rhea-AI Summary
Cellectar Biosciences, a late-stage clinical biopharmaceutical company (NASDAQ: CLRB), announced a partnership with American Oncology Network (AON) and Meaningful Insights-BioTech Analytics (MiBA) to advance the treatment of Waldenstrom's macroglobulinemia (WM) in the community setting. Positive topline data from the pivotal Clover WaM study for iopofosine I 131 was reported, achieving a 61% major response rate (MRR) and exceeding the protocol statistical hurdle of 20%. The partnership aims to enrich the WM treatment paradigm and optimize outcomes with iopofosine I 131 upon FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
partnership
-
News
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
Rhea-AI Summary
Cellectar Biosciences, a late-stage clinical biopharmaceutical company (NASDAQ: CLRB), announced data from its CLOVER WaM pivotal study, evaluating iopofosine I 131, a targeted radiotherapy candidate for the treatment of relapsed/refractory Waldenstrom’s macroglobulinemia patients. The study met its primary endpoint with a major response rate (MRR) of 61% and an overall response rate (ORR) of 75.6%. The drug achieved a 100% disease control rate, with durable responses and a promising safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.08%
Tags
clinical trial
-
News
Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) to Host Conference Call and Present at Biotech Showcase
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
none
News
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announces exclusive license agreement with WARF for iopofosine I 131 in pediatric cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
-
News
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) has received expanded global patent protection for its Phospholipid Drug Conjugate™ (PDC) platform to deliver flavaglines as targeted anticancer payloads. The patent covers composition of matter and use protection for the PDC platform in combination with flavaglines in key global regions, including Japan, China, Eurasia, Brazil, and Mexico, following prior allowances in the US, Europe, Australia, and Canada. This expansion supports Cellectar's plan to develop a diverse product portfolio beyond radiotherapies, with a focus on reporting topline data for its lead radioconjugate therapy, iopofosine I 131, in January 2024, and expanding its pipeline of PDCs in high-need cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
News
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced that its COO, Jarrod Longcor, will deliver a presentation and co-chair the 5th Annual Targeted Radiopharmaceuticals Summit Europe in Berlin, Germany. The presentation will focus on advancing universal targeted radiotherapies for solid and hematologic malignancies, highlighting the company's proprietary PLE delivery platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
News
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
Rhea-AI Summary
Cellectar Biosciences, Inc. reports preliminary financial results for Q3 2023, including $19.0 million in cash and cash equivalents. They closed a private placement financing with potential gross proceeds of up to $102.9 million. The company also received PRIME designation for iopofosine I 131 and expanded their intellectual property portfolio. They plan to release top-line data from the pivotal trial in Waldenstrom’s macroglobulinemia (WM) during the JP Morgan Healthcare conference in January 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
News
Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
Rhea-AI Summary
Cellectar Biosciences announced a partnership with Florida Cancer Specialists & Research Institute to advance patient care and define the treatment landscape for Waldenstrom's macroglobulinemia (WM) in the community oncology setting. The collaboration aims to evaluate unmet needs and optimize novel therapies for WM patients. Cellectar expects to release top-line data from its pivotal trial in 4Q 2023 and remains on target for a 2024 US product launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
partnership
-
News
Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023
Rhea-AI Summary
Cellectar Biosciences to report Q3 2023 financial results on November 2 and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
earnings
News
Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia
Rhea-AI Summary
Cellectar Biosciences appoints William Yoon as VP of Medical Affairs and Aaditya Nanduri as VP of Business Strategy and Analytics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
management
Stock CLRB logo
Cellectar Biosciences Inc

Nasdaq:CLRB

CLRB Rankings

#4281 Ranked by Market Cap
#1026 Ranked by Stock Gains
N/A Ranked by Dividends

CLRB Stock Data

113.23M
24.62M
3.57%
30.47%
7.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Florham Park

About CLRB

cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p